These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 9834251)
101. GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells. Rooney IA; Heuser JE; Atkinson JP J Clin Invest; 1996 Apr; 97(7):1675-86. PubMed ID: 8601633 [TBL] [Abstract][Full Text] [Related]
102. Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. Alfinito F; Del Vecchio L; Rocco S; Boccuni P; Musto P; Rotoli B Leukemia; 1996 Aug; 10(8):1326-30. PubMed ID: 8709638 [TBL] [Abstract][Full Text] [Related]
103. Phenotypic analysis of affected peripheral erythroid for CD59 in paroxysmal nocturnal hemoglobinuria. Cui W; Lin Q; Zhang Z Chin Med J (Engl); 2002 Feb; 115(2):206-8. PubMed ID: 11940332 [TBL] [Abstract][Full Text] [Related]
104. Induction of Fc gamma R-III (CD16) expression on neutrophils affected by paroxysmal nocturnal haemoglobinuria by administration of granulocyte colony-stimulating factor. Ninomiya H; Muraki Y; Shibuya K; Nagasawa T; Abe T Br J Haematol; 1993 Jul; 84(3):497-503. PubMed ID: 7692930 [TBL] [Abstract][Full Text] [Related]
105. Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria. Gao W; Wang Z; Bai X; Li Y; Ruan C Int J Hematol; 2002 May; 75(4):434-9. PubMed ID: 12041678 [TBL] [Abstract][Full Text] [Related]
106. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. Risitano AM; Frieri C; Urciuoli E; Marano L Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036 [TBL] [Abstract][Full Text] [Related]
107. Differential usefulness of various markers in the flow cytometric detection of paroxysmal nocturnal hemoglobinuria in blood and bone marrow. Olteanu H; Karandikar NJ; McKenna RW; Xu Y Am J Clin Pathol; 2006 Nov; 126(5):781-8. PubMed ID: 17050075 [TBL] [Abstract][Full Text] [Related]
108. [Evolution of paroxysmal nocturnal hemoglobinuria clone during an hemolytic crisis in a patient with aplastic anemia. Flow cytometry study]. Canalejo K; Galassi N; Riera N; Bengió R; Aixalá M Medicina (B Aires); 2001; 61(5 Pt 1):581-4. PubMed ID: 11721326 [TBL] [Abstract][Full Text] [Related]
109. Cells lacking glycan phosphatidylinositol-linked proteins have impaired ability to vesiculate. Whitlow M; Iida K; Marshall P; Silber R; Nussenzweig V Blood; 1993 Jan; 81(2):510-6. PubMed ID: 7678519 [TBL] [Abstract][Full Text] [Related]
110. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection. Dammermann W; Schipper P; Ullrich S; Fraedrich K; Schulze Zur Wiesch J; Fründt T; Tiegs G; Lohse A; Lüth S PLoS One; 2013; 8(9):e74880. PubMed ID: 24086391 [TBL] [Abstract][Full Text] [Related]
111. Paroxysmal nocturnal hemoglobinuria clone in bone marrow of patients with pancytopenia. Nakakuma H; Nagakura S; Iwamoto N; Kawaguchi T; Hidaka M; Horikawa K; Kagimoto T; Shido T; Takatsuki K Blood; 1995 Mar; 85(5):1371-6. PubMed ID: 7532041 [TBL] [Abstract][Full Text] [Related]
112. Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Hosokawa K; Sugimori C; Ishiyama K; Takamatsu H; Noji H; Shichishima T; Obara N; Chiba S; Ninomiya H; Shirasugi Y; Nakamura Y; Ando K; Ueda Y; Yonemura Y; Kawaguchi T; Nishimura JI; Kanakura Y; Nakao S Ann Hematol; 2018 Dec; 97(12):2289-2297. PubMed ID: 30039297 [TBL] [Abstract][Full Text] [Related]
113. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ Blood; 1990 Jan; 75(1):284-9. PubMed ID: 1688497 [TBL] [Abstract][Full Text] [Related]
114. Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria. Colden MA; Kumar S; Munkhbileg B; Babushok DV Front Immunol; 2021; 12():830172. PubMed ID: 35154088 [TBL] [Abstract][Full Text] [Related]
116. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. Hillmen P; Horneff R; Yeh M; Kolev M; Deschatelets P Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273426 [TBL] [Abstract][Full Text] [Related]
117. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Ploug M; Plesner T; Rønne E; Ellis V; Høyer-Hansen G; Hansen NE; Danø K Blood; 1992 Mar; 79(6):1447-55. PubMed ID: 1312369 [TBL] [Abstract][Full Text] [Related]
118. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. DeZern AE; Uknis M; Yuan X; Mukhina GL; Varela J; Saye J; Pu J; Brodsky RA Exp Hematol; 2014 Oct; 42(10):857-61.e1. PubMed ID: 25034232 [TBL] [Abstract][Full Text] [Related]